Lakefront Biotherapeutics (LKFT)
Develops and acquires autoimmune T-cell engager medicines with Gilead.
Acquisition of Own Shares
Mechelen, Belgium; 01 September 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 24, 2026 and August 28, 2026 it has repurchased 127,796 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 24/08/2026 XAMS 21,820 24.56 535,857.74 24.36 24.64 24/08/2026 TQEX 450 24.55 11,045.43 24.54 24.60 24/08/2026 CEUX 328 24.58 8,062.37 24.54 24.64 24/08/2026 AQEU 1,333 24.61 32,811.40 24.58 24.66 25/08/2026 XAMS 21,058 25.29 532,464.16 24.94 25.52 25/08/2026 TQEX 698 25.25 17,623.66 25.00 25.36 25/08/2026 CEUX 600 25.28 15,165.48 25.24 25.34 25/08/2026 AQEU 313 25.29 7,914.33 25.26 25.34 26/08/2026 XAMS 22,968 25.45 584,632.07 25.08 25.64 26/08/2026 TQEX 599 25.45 15,241.91 25.30 25.64 26/08/2026 CEUX 1,703 25.47 43,377.62 25.24 25.66 26/08/2026 AQEU 539 25.50 13,744.72 25.32 25.60 27/08/2026 XAMS 21,382 25.27 540,406.53 25.06 25.36 27/08/2026 TQEX 904 25.27 22,843.72 25.20 25.32 27/08/2026 CEUX 2,342 25.24 59,114.89 25.12 25.36 27/08/2026 AQEU 440 25.23 11,100.50 25.12 25.34 28/08/2026 XAMS 25,694 25.29 649,927.16 25.00 25.50 28/08/2026 TQEX 1,110 25.40 28,194.11 25.36 25.46 28/08/2026 CEUX 3,363 25.38 85,342.18 25.08 25.46 28/08/2026 AQEU 152 25.26 3,840.17 25.14 25.46 Total 127,796 25.19 3,218,710.15 24.36 25.66 As of market close on 28 August 2026, Lakefront holds 1,161,324 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.
Acquisition of Own Shares
Mechelen, Belgium; 25 August 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 17, 2026 and August 21, 2026, it has repurchased 117,471 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 17/08/2026 XAMS 16,158 23.97 387,350.89 23.84 24.20 17/08/2026 CEUX 2,196 23.98 52,664.03 23.90 24.18 17/08/2026 TQEX 611 24.07 14,706.59 23.94 24.20 17/08/2026 AQEU 1,008 24.04 24,227.68 23.94 24.04 18/08/2026 XAMS 23,094 23.82 550,184.53 23.66 24.00 18/08/2026 CEUX 2,137 23.79 50,833.25 23.66 23.94 18/08/2026 TQEX 737 23.87 17,593.07 23.70 23.90 18/08/2026 AQEU 562 23.82 13,389.14 23.72 23.86 19/08/2026 XAMS 16,677 24.83 414,059.89 24.16 25.70 19/08/2026 CEUX 1,953 24.67 48,186.37 24.36 25.52 19/08/2026 TQEX 1,329 24.52 32,583.23 24.36 24.66 19/08/2026 AQEU 224 24.59 5,507.89 24.40 24.60 20/08/2026 XAMS 24,144 24.92 601,772.30 24.36 25.68 20/08/2026 CEUX 2,709 25.29 68,501.13 25.10 25.70 20/08/2026 TQEX 962 24.89 23,940.04 24.44 25.14 20/08/2026 AQEU 1,209 25.25 30,521.69 25.10 25.42 21/08/2026 XAMS 14,694 24.38 358,210.33 24.14 25.00 21/08/2026 CEUX 5,347 24.31 130,010.17 24.18 24.84 21/08/2026 TQEX 381 24.57 9,360.83 24.24 24.90 21/08/2026 AQEU 1,339 24.22 32,432.05 24.22 24.24 Total 117,471 24.40 2,866,035.10 23.66 25.70 As of market close on 21 August 2026, Lakefront holds 1,033,528 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.
U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus
Mechelen, Belgium; 24 August 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to gamgertamig for the treatment of pemphigus. Gamgertamig was previously granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP).
Lakefront Receives Transparency Notification from Bank of America
Mechelen, Belgium; August 24, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America.
Acquisition of Own Shares
Mechelen, Belgium; 18 August 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 10, 2026 and August 14, 2026, it has repurchased 107,871 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 10/08/2026 XAMS 18,754 23.53 441,208.48 23.24 23.64 10/08/2026 AQEU 1 23.54 23.54 23.54 23.54 10/08/2026 CEUX 2,234 23.42 52,317.60 23.28 23.62 10/08/2026 TQEX 551 23.46 12,927.51 23.32 23.64 11/08/2026 XAMS 14,810 24.07 356,417.46 22.88 24.52 11/08/2026 CEUX 1,014 24.12 24,453.02 23.76 24.48 11/08/2026 TQEX 496 24.34 12,070.26 24.04 24.42 12/08/2026 XAMS 19,360 24.64 476,972.32 24.40 24.98 12/08/2026 AQEU 310 24.59 7,622.28 24.46 24.62 12/08/2026 CEUX 764 24.53 18,744.36 24.44 24.64 12/08/2026 TQEX 141 24.48 3,451.82 24.46 24.54 13/08/2026 XAMS 18,473 24.40 450,696.86 24.20 24.50 13/08/2026 AQEU 13 24.40 317.20 24.40 24.40 13/08/2026 CEUX 3,090 24.38 75,331.11 24.18 24.50 13/08/2026 TQEX 1,381 24.41 33,706.07 24.34 24.50 14/08/2026 XAMS 23,317 24.09 561,603.94 23.76 24.42 14/08/2026 AQEU 163 24.09 3,927.39 23.94 24.16 14/08/2026 CEUX 2,337 24.06 56,217.70 23.90 24.24 14/08/2026 TQEX 662 24.16 15,993.66 23.90 24.36 Total 107,871 24.14 2,604,002.56 22.88 24.98 As of market close on 14 August 2026, Lakefront holds 916,057 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.
Acquisition of Own Shares
Mechelen, Belgium; 12 August 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 3, 2026 and August 7, 2026, it has repurchased 103,970 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 03/08/2026 XAMS 16,017 23.56 377,368.53 23.10 23.86 03/08/2026 CEUX 2,367 23.61 55,891.02 23.26 23.84 03/08/2026 AQEU 876 23.70 20,761.46 23.70 23.72 03/08/2026 TQEX 704 23.75 16,720.35 23.62 23.86 04/08/2026 XAMS 17,257 23.31 402,305.54 23.18 23.48 04/08/2026 CEUX 2,485 23.26 57,801.85 23.18 23.40 04/08/2026 AQEU 55 23.24 1,278.20 23.24 23.24 04/08/2026 TQEX 722 23.33 16,842.60 23.20 23.40 05/08/2026 XAMS 17,763 23.17 411,650.42 22.96 23.32 05/08/2026 CEUX 2,382 23.12 55,068.98 22.90 23.28 05/08/2026 AQEU 604 23.18 14,003.62 23.08 23.24 05/08/2026 TQEX 170 23.20 3,944.00 23.20 23.20 06/08/2026 XAMS 17,857 22.64 404,205.69 22.32 22.88 06/08/2026 CEUX 1,987 22.49 44,681.07 22.36 22.70 06/08/2026 AQEU 743 22.65 16,831.55 22.42 22.72 06/08/2026 TQEX 533 22.57 12,030.61 22.44 22.76 07/08/2026 XAMS 17,738 23.24 412,179.68 22.88 23.44 07/08/2026 CEUX 2,842 23.26 66,112.88 23.12 23.40 07/08/2026 AQEU 199 23.29 4,634.37 23.26 23.38 07/08/2026 TQEX 669 23.30 15,588.97 23.18 23.46 Total 103,970 23.18 2,409,901.40 22.32 23.86 As of market close on 07 August 2026, Lakefront holds 808,186 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.
Inkoop van eigen aandelen
Mechelen, België; 28 juli 2026, 22. 01 CET; gereglementeerde informatie In het kader van het op 9 juni 2026 aangekondigde inkoopprogramma maakt Lakefront Biotherapeutics NV (Euronext and NASDAQ: LKFT) ("Lakefront") bekend dat het tussen 20 juli 2026 en 24 juli 2026 via een discretionair mandaat aan een onafhankelijke financiële tussenpartij 95. 670 Lakefront-aandelen heeft ingekocht, als volgt: Bij het sluiten van de beurs op 24 juli 2026 hield Lakefront 606. 719 van zijn eigen gewone aandelen aan. Over Lakefront BiotherapeuticsLakefront Biotherapeutics (voorheen bekend als Galapagos) is een biotechnologiebedrijf dat zich richt op de uitbouw van een gedifferentieerde geneesmiddelenpijplijn voor patiënten met ernstige aandoeningen waarvoor nog een grote onvervulde medische nood bestaat.
Acquisition of Own Shares
Mechelen, Belgium; July 28, 2026, 22. 01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext and NASDAQ: LKFT) ("Lakefront") announces that between July 20, 2026 and July 24, 2026, it has repurchased 95,670 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: As of market close on July 24, 2026, Lakefront holds 606,719 of its own ordinary shares.
Acquisition of Own Shares
Mechelen, Belgium; July 28, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between July 20, 2026 and July 24, 2026, it has repurchased 95,670 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 20/07/2026 XAMS 17,936 26.05 467,150.29 25.62 26.40 20/07/2026 CEUX 3,372 25.79 86,979.73 25.70 26.14 20/07/2026 AQEU 101 25.72 2,597.72 25.72 25.72 20/07/2026 TQEX 74 26.22 1,940.28 26.22 26.22 21/07/2026 XAMS 14,022 25.59 358,820.18 25.34 25.80 21/07/2026 CEUX 1,506 25.57 38,513.84 25.52 25.66 21/07/2026 AQEU 227 25.53 5,795.01 25.52 25.70 21/07/2026 TQEX 506 25.56 12,931.79 25.52 25.58 22/07/2026 XAMS 15,385 25.61 394,028.31 25.48 25.72 22/07/2026 CEUX 1,245 25.63 31,907.36 25.62 25.68 22/07/2026 AQEU 490 25.62 12,553.80 25.62 25.62 22/07/2026 TQEX 185 25.68 4,750.13 25.62 25.68 23/07/2026 XAMS 17,120 25.13 430,292.37 24.70 25.62 23/07/2026 CEUX 2,945 24.81 73,071.34 24.74 25.12 23/07/2026 AQEU 61 24.78 1,511.58 24.78 24.78 23/07/2026 TQEX 61 24.78 1,511.58 24.78 24.78 24/07/2026 XAMS 17,407 24.81 431,940.78 24.56 25.00 24/07/2026 CEUX 1,729 24.77 42,830.62 24.60 24.98 24/07/2026 AQEU 1,159 24.91 28,875.91 24.62 24.96 24/07/2026 TQEX 139 24.75 3,439.68 24.62 24.92 Total 95,670 25.41 2,431,442.30 24.56 26.40 As of market close on July 24, 2026, Lakefront holds 606,719 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.
Acquisition of Own Shares
Mechelen, Belgium; July 21, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between July 13, 2026 and July 17, 2026 it has repurchased 98,648 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 13/07/2026 XAMS 20,583 26.38 543,006.30 26.12 26.56 13/07/2026 CEUX 1,842 26.39 48,613.33 26.30 26.54 13/07/2026 AQEU 238 26.41 6,286.13 26.34 26.54 13/07/2026 TQEX 532 26.41 14,049.69 26.34 26.46 14/07/2026 XAMS 19,825 26.01 515,672.04 25.74 26.34 14/07/2026 CEUX 2,289 25.99 59,486.07 25.84 26.20 14/07/2026 AQEU 170 25.86 4,396.20 25.86 25.86 14/07/2026 TQEX 987 26.08 25,736.81 26.06 26.18 15/07/2026 XAMS 15,770 25.75 406,156.35 25.62 25.96 15/07/2026 CEUX 422 25.73 10,857.47 25.62 25.78 15/07/2026 AQEU 476 25.72 12,244.15 25.62 25.76 15/07/2026 TQEX 906 25.79 23,368.73 25.62 25.80 16/07/2026 XAMS 16,485 25.93 427,428.03 25.76 26.10 16/07/2026 CEUX 1,137 25.93 29,483.89 25.88 26.00 16/07/2026 AQEU 68 25.92 1,762.56 25.92 25.92 16/07/2026 TQEX 528 25.94 13,695.21 25.92 25.94 17/07/2026 XAMS 14,972 25.77 385,768.55 25.60 26.04 17/07/2026 CEUX 1,368 25.83 35,337.22 25.70 26.02 17/07/2026 TQEX 50 25.70 1,285.00 25.70 25.70 Total 98,648 26.00 2,564,633.73 25.60 26.56 As of market close on July 17, 2026, Lakefront holds 511,049 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.
Acquisition of Own Shares
Mechelen, Belgium; 14 July 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 108,645 Lakefront shares between 06 July 2026 and 10 July 2026, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 06/07/2026 XAMS 20,236 26.54 536,964.28 26.20 26.90 06/07/2026 CEUX 2,499 26.69 66,710.06 26.32 26.90 06/07/2026 TQEX 355 26.72 9,486.20 26.52 26.90 06/07/2026 AQEU 319 26.58 8,477.65 26.52 26.88 07/07/2026 XAMS 16,553 26.65 441,104.34 26.40 26.86 07/07/2026 CEUX 1,578 26.55 41,894.01 26.44 26.76 07/07/2026 TQEX 821 26.64 21,872.92 26.60 26.70 07/07/2026 AQEU 49 26.60 1,303.40 26.60 26.60 08/07/2026 XAMS 17,502 26.84 469,793.93 26.66 27.00 08/07/2026 CEUX 4,339 26.89 116,674.84 26.74 26.96 08/07/2026 TQEX 1,157 26.87 31,086.62 26.76 26.94 08/07/2026 AQEU 416 26.86 11,172.18 26.80 26.94 09/07/2026 XAMS 16,919 26.77 452,892.87 26.56 26.90 09/07/2026 CEUX 2,717 26.79 72,781.09 26.70 26.96 09/07/2026 TQEX 23 26.76 615.48 26.76 26.76 09/07/2026 AQEU 400 26.77 10,707.04 26.76 26.78 10/07/2026 XAMS 19,764 26.52 524,208.48 26.14 26.90 10/07/2026 CEUX 2,009 26.66 53,568.98 26.26 26.92 10/07/2026 TQEX 692 26.65 18,443.74 26.24 26.78 10/07/2026 AQEU 297 26.82 7,964.53 26.26 26.92 Total 108,645 26.67 2,897,722.65 26.14 27.00 As of market close on 10 July 2026, Lakefront holds 412,401 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.
Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi
Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext and NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research and Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.
Lakefront kondigt het terugtreden van Paulo Fontoura uit de Raad van Bestuur aan na zijn benoeming tot Global Head of Research & Development bij Sanofi
Mechelen, België; 13 juli 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext and NASDAQ: LKFT) heeft vandaag bekendgemaakt dat dr. Paulo Fontoura, na zijn benoeming tot Executive Vice President en Global Head of Research and Development Pharma bij Sanofi SA, zijn mandaat als lid van de Raad van Bestuur heeft neergelegd. "Ik wil Paulo feliciteren met deze belangrijke benoeming en hem oprecht bedanken voor zijn inzichten en begeleiding tijdens zijn ambtstermijn in onze Raad van Bestuur.
Acquisition of Own Shares
Mechelen, Belgium; 07 July 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 104,022 Lakefront shares between 29 June 2026 and 03 July 2026, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 29/06/2026 XAMS 14,414 25.75 371,205.18 25.60 26.00 29/06/2026 CEUX 3,399 25.74 87,478.36 25.66 26.00 29/06/2026 TQEX 696 25.71 17,897.29 25.66 26.00 29/06/2026 AQEU 916 25.71 23,551.83 25.66 25.80 30/06/2026 XAMS 19,724 26.37 520,179.08 25.98 26.74 30/06/2026 CEUX 2,068 26.45 54,694.67 26.22 26.72 30/06/2026 TQEX 508 26.53 13,478.15 26.14 26.78 30/06/2026 AQEU 445 26.09 11,610.94 26.08 26.12 01/07/2026 XAMS 20,787 26.30 546,681.47 26.06 26.48 01/07/2026 CEUX 2,613 26.20 68,467.39 26.12 26.44 01/07/2026 TQEX 71 26.40 1,874.32 26.32 26.40 01/07/2026 AQEU 198 26.17 5,181.78 26.16 26.30 02/07/2026 XAMS 13,778 26.14 360,180.34 25.88 26.54 02/07/2026 CEUX 3,021 26.06 78,727.86 25.96 26.12 02/07/2026 TQEX 115 26.23 3,015.94 25.96 26.46 02/07/2026 AQEU 721 26.12 18,835.04 25.96 26.14 03/07/2026 XAMS 15,162 26.62 403,642.76 26.46 26.86 03/07/2026 CEUX 4,786 26.59 127,266.92 26.50 26.86 03/07/2026 TQEX 526 26.75 14,071.18 26.50 26.88 03/07/2026 AQEU 74 26.62 1,970.16 26.52 26.64 Total 104,022 26.24 2,730,010.70 25.60 26.88 As of market close on 03 July 2026, Lakefront holds 303,756 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.
Acquisition of Own Shares
Mechelen, Belgium; 30 June 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 83,530 Lakefront shares between 22 June 2026 and 26 June 2026, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 22/06/2026 XAMS 15,297 24.59 376,162.41 24.38 24.96 23/06/2026 XAMS 15,050 25.32 381,076.53 25.06 25.52 24/06/2026 XAMS 18,944 25.55 483,992.68 25.30 25.78 25/06/2026 XAMS 17,239 25.41 438,065.40 25.12 25.72 26/06/2026 XAMS 17,000 25.22 428,748.50 24.94 25.82 Total 83,530 25.24 2,108,045.52 24.38 25.82 As of market close on 26 June 2026, Lakefront holds 199,734 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.
Acquisition of Own Shares
Mechelen, Belgium; 23 June 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 77,667 Lakefront shares between 15 June 2026 and 19 June 2026, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 15/06/2026 EXNT 13,272 24.9331 330,912.10 24.7200 25.2200 16/06/2026 EXNT 16,400 24.5495 402,611.80 24.1200 25.2600 17/06/2026 EXNT 13,605 24.4212 332,250.43 24.0000 24.7800 18/06/2026 EXNT 16,960 24.8036 420,669.06 24.4800 25.1200 19/06/2026 EXNT 17,430 24.5966 428,718.74 24.3600 24.7600 Total 77,667 24.6586 1,915,162.13 24.3360 25.0280 As of market close on 19 June 2026, Lakefront holds 116,204 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.
Acquisition of Own Shares
Mechelen, Belgium; June 16, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 38,537 Lakefront shares between June 9, 2026 and June 12, 2026, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 10-Jun-2026 ENXT 13,019 24.6037 320,315.57 24.3600 25.0800 11-Jun-2026 ENXT 12,563 24.8024 311,592.55 24.5400 24.9200 12-Jun-2026 ENXT 12,955 24.9248 322,900.78 24.8000 25.0400 Total 38,537 24.7764 954,808.90 24.3600 25.0800 As of market close on June 12, 2026, Lakefront holds 38,537 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.
Lakefront Announces Initiation of €50 Million Stock Repurchase Program
Mechelen, Belgium ; June 9, 2026, 22:01 CET; regulated information – Lakefront Bio therapeutics NV (Euronext & NASDAQ: LKFT) today announced the launch of a share repurchase program (the “Program”), under which the Company may repurchase ordinary shares for an aggregate amount of up to €50 Million. Repurchases under the Program may be made no later than December 31, 2026. The Program is entered into with Morgan Stanley & Co International PLC.
Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer
Mechelen, Belgium ; June 8, 2026, 22:01 CET; Lakefront Bio therapeutics NV (Euronext & NASDAQ: LKFT) today announced that Eric Hedrick, MD has been appointed Chief Medical Officer. This expanded leadership role supports the Company's strategic transformation following its acquisition of Ouro Medicines operational assets announced on June 4, 2026. 1 Eric will report to Henry Gosebruch, CEO and join the Company's Management Committee.